These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10442372)

  • 1. UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group.
    Hata Y; Uchino J; Asaishi K; Kubo Y; Mito M; Tanabe T; Ogita M; Hirata K
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):91-5. PubMed ID: 10442372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer.
    Sugimachi K; Maehara Y; Akazawa K; Nomura Y; Eida K; Ogawa M; Konaga E; Tanaka N; Toge T; Dohi K; Noda S; Maeda M; Monden Y
    Breast Cancer Res Treat; 1999 Jul; 56(2):113-24. PubMed ID: 10573104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy for advanced breast cancer: cyclophosphamide, doxorubicin, UFT, and tamoxifen.
    Fukuda M; Yamaguchi S; Ohta T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):77-81. PubMed ID: 10442369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
    Toi M; Ikeda T; Akiyama F; Kurosumi M; Tsuda H; Sakamoto G; Abe O
    Int J Oncol; 2007 Oct; 31(4):899-906. PubMed ID: 17786323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UFT in combination as adjuvant therapy for breast cancer. Grupo Oncologico de Sevilla Seville, Spain.
    Iglesias L; Moreno JA; Torrija E; Murillo E; Codes M; Dugue A; Garcia E; Virizuela JA
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):74-81. PubMed ID: 9348574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
    Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
    J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
    Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
    Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
    Yoshida M; Saji S; Takagi H; Takeuchi S; Tsuda H; Nimura Y; Mizumoto R; Miyazaki I; Kobayashi S; Noguchi M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2325-33. PubMed ID: 8259846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxifen plus UFT for Estrogen-Receptor-Negative Breast Cancer : Adjuvant Therapy after Administration of Mitomycin.
    Ogita M; Uchino J; Asaishi K; Kubo Y; Tanabe T; Hata A; Hirata K; Mito M;
    Clin Drug Investig; 2003; 23(11):689-99. PubMed ID: 17536882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial).
    Ohashi Y; Watanabe T; Sano M; Koyama H; Inaji H; Suzuki T
    Breast Cancer Res Treat; 2010 Feb; 119(3):633-41. PubMed ID: 19936917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine plus uracil/tegafur therapy for prostate cancer.
    Ono Y; Ohshima S; Takahashi Y; Kuriyama M; Kawada Y; Shimizu H
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):120-4. PubMed ID: 10442379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant chemotherapy with mitomycin C and UFT for rectal cancer.
    Kodaira S
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):40-3. PubMed ID: 9348566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [UFT-MT therapy in advanced or recurrent breast cancer].
    Yamaguchi S; Komoriyama H; Tsukikawa S; Imaki S; Morikubo M; Asakura T; Okamura R; Fukuda M; Kanasugi K; Watanabe H
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2437-41. PubMed ID: 2124435
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial.
    Hasegawa K; Takayama T; Ijichi M; Matsuyama Y; Imamura H; Sano K; Sugawara Y; Kokudo N; Makuuchi M
    Hepatology; 2006 Oct; 44(4):891-5. PubMed ID: 17006925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
    Ejlertsen B; Jensen MB; Elversang J; Rasmussen BB; Andersson M; Andersen J; Nielsen DL; Cold S; Mouridsen HT
    Eur J Cancer; 2013 Sep; 49(14):2986-94. PubMed ID: 23756360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer].
    Abe R; Tsuchiya A; Koie H; Ono K; Abo S; Saito K; Tsukamoto M; Sato T; Mori S; Motoki R
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2707-12. PubMed ID: 3137888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.